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Abstract
We describe the frequency, clinical features, and electrophysiological and immunological phenotypes of Guillain-Barré
Syndrome (GBS) patients treated at a single institution in Bangladesh who had preceding chicken pox (primary Varicella-
zoster virus [VZV] infection) within 4 weeks of GBS onset. A literature review of GBS cases preceding VZV infection is also
provided. Diagnosis of GBS was based on the National Institute of Neurological Disorders and Stroke criteria for GBS. Serum
anti-VZV IgM and IgG antibodies were quantified by indirect chemiluminescence immunoassay (CLIA); anti-Campylobacter
jejuni IgG, IgM, and IgA antibodies and anti-ganglioside GM1 IgM and IgG antibodies, by enzyme-linked immunosorbent
assays. Neurophysiologic subtypes were categorized following the Hadden criteria. Of 536 patients with GBS, 7 (1.3%) had
chicken pox within 4 weeks before GBS onset. Four of the seven cases were male (age range, 23 to 40 years old). All seven
patients were bed-bound, six had sensory symptoms, and three required mechanical ventilation for respiratory failure. All seven
patients had CSF albuminocytologic dissociation and evidence of demyelination in nerve conduction studies. Anti-VZV IgM
antibodies were present and anti-GM1 and anti-Campylobacter jejuni lipo-oligosaccharides (LOS) were negative in all cases. All
patients had excellent outcome at 1 year (able to run). A systematic literature review of GBS cases related to VZV revealed 39
previously reported patients with comparable clinical presentations and outcomes, of which 36 had neurophysiologic evidence of
demyelination. VZVinfection is associated with the demyelinating subtype of GBS, clearly distinct from the axonal form of GBS
that predominate in countries like Bangladesh.
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Introduction
Preceding infections are the predominant trigger of Guillain-
Barré Syndrome (GBS) [1]. Current evidence suggests spe-
cific antecedent infections can influence the clinical pheno-
type, course, and outcome of GBS. Among the GBS-related
pathogens that have been extensively studied, Campylobacter
jejuni is associated with acute motor axonal neuropathy
(AMAN) presenting with severe weakness and poor outcome
[2, 3]. Similarly, cytomegalovirus infections are associated
with sensory-motor acute inflammatory demyelinating
polyneuropathy (AIDP) [4]. Epstein-Barr virus, hepatitis E
virus, Mycoplasma pneumonia, varicella-zoster virus
(VZV), and Zika virus have also been related to GBS, though
the associated clinical and electrophysiological variants are
less well-defined [1, 5, 6]. The type of preceding infection
may also influence the differences in the frequency of GBS
variants observed between geographical regions. In
Bangladesh, the frequency of preceding C. jejuni infections
is around 50% [3], which may explain the exceptionally high
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frequency of AMAN compared to other regions. Other Asian
and South American countries have also reported higher fre-
quencies of AMAN [2, 7–9] compared to Europe and North
American countries, where AIDP is the predominant variant
[10, 11]. Other than C. jejuni, the preceding infections in
patients with GBS from Bangladesh are not well-defined.
Infection with VZV has been reported as a rare preceding
event in GBS, mainly described in case reports. One
population-based study revealed an increased risk of GBS
following herpes zoster attack, though information on clinical
and neurophysiologic subtype(s) was lacking [12]. Here, we
report the frequency of preceding chickenpox or varicella
infection in a cohort of 536 consecutive patients with GBS
from Bangladesh and provide detailed analyses of the asso-
ciated clinical and electrophysiological features. An overview
of 39 previously reported VZV-related GBS cases [13–42] is
also provided, and probable pathogenesis are discussed.
Methods
Patients
Between March 2010 and June 2016, 536 patients with GBS
of all ages presenting within 2 weeks of the onset of weakness
at Dhaka Medical College Hospital (DMCH) have been pro-
spectively enrolled. Diagnosis of GBS was as per the National
Institute of Neurological Disorders and Stroke criteria for
GBS [43]. Patients with GBS having clinical features of pri-
maryVZV (chicken pox) infection within 4 weeks of the onset
of weakness were included in this study. Data were collected
regarding clinical presentation, specifically severity of weak-
ness (GBS disability score and MRC sum score), sensory
disturbance, cranial nerve dysfunction, dysautonomia, CSF
analysis, and nerve conduction study results. Patients were
followed up at fixed intervals for 1 year to observe neurolog-
ical outcome. All the patients provided informed written con-
sent and the study was approved by the ethical bodies of the
International Centre for Diarrhoeal Disease Research,
Bangladesh (icddr,b) and DMCH.
Immunological assays
Serum anti-VZV IgM and IgG antibodies were quantified
using indirect chemiluminescence immunoassay (CLIA) on
DiaSorin-LIAISON® XL (DiaSorin S.p.A, Vercelli, Italy) at
the Department of Viroscience, ErasmusMC, Rotterdam. The
cutoff for IgM positivity was 1.1 S/CO; values between 0.9–
1.1 S/CO were interpreted as equivocal following the manu-
facturer’s instructions. Anti-C. jejuni IgG antibodies were
measured using an indirect enzyme-linked immunosorbent
assay (ELISA); anti-C. jejuni IgM and IgA antibodies, by
antibody class capture ELISAs based on previously described
positivity criteria [44]. Serum anti-GM1 IgG antibodies and
antibody reactivity to C. jejuni LOS were assessed using
ELISAs at the icddr,b. Patients were considered positive for
anti-GM1 IgG antibodies if the optical density was > 0.2 [3].
Serum antibodies against LOS were quantified using an
ELISA as described previously [45] with some modifications
[46]. Serum was considered anti-LOS positive if the corrected
OD was greater than the mean plus three times standard devi-
ation (SD) value of control samples.
Nerve conduction studies
Nerve conduction studies (NCS) were performed on one side
of the body according to standardized and strict protocols
using a Viking Select EMG system (CareFusion, San Diego,
CA, USA). Neurophysiologic subtypes of GBS were catego-
rized as per the Hadden criteria [7].
Literature review
A systematic literature review was conducted using PubMed/
MEDLINE and EBSCO. No timeframe was selected; search
terms were BGuillain-Barre syndrome,^ Bchickenpox,^ Bvari-
cella,^ Bshingles,^ and Bherpes zoster.^
Statistical analysis
Categorical data are presented as numbers, percentages, and
proportions; numerical data, as medians and interquartile
ranges (IQRs). Differences in proportions were examined
using Fisher’s exact test and median values using the
Wilcoxon-Mann-Whitney U test with SPSS 22 software
(IBM SPSS Statistics for Windows Version 22.0; IBM
Corp., Armonk, NY, USA). P values are two-sided;
P < 0.005 after Bonferroni correction was considered
significant.
Results
Patients and clinical features
Seven out of 536 (1.3%) patients with GBS had fever and
generalized vesicular skin eruption characteristic of chicken
pox or varicella, within 4 weeks before the onset of weakness.
Demographic and clinical features, CSF and NCS subtypes,
serological and immunological findings, and outcomes are
summarized in Table 1. Four of the seven cases were male;
age ranged from 23 to 40 years old. Primary VZV skin erup-
tion within 2 weeks of the onset of weakness was present in
five patients and within 4 weeks in two patients. Six of the
seven patients had the sensory-motor subtype of GBS; all
were bed-bound with MRC sum scores ranging from 8 to
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Table 1 Clinical features of GBS
associated with varicella-zoster
virus (VZV) infection







Age, years (median, IQR) 34 (29–38) 32 (9–42) 66 (57–74)b
Male/female ratio 4/3 17/7 10/5
VZV skin lesions to weakness, days
(median, IQR)
11 (10–18) 8 (7–13) 10 (8–28)
Clinical type
Sensory-motor 6/7 (86%) 13/24 (54%) 14/15 (93%)
Pure motor 1/7 (14%) 11/24 (46%) 1/15 (7%)
Severity of weakness
Tetraparesis 7/7 (100%) 20/24 (83%) 15/15 (100%)
Paraparesis 0/7 (0%) 4/24 (17%) 0/15 (0%)
Deep tendon reflex
Hypo/absent 7/7 (100%) 23/24 (96%) 15/15 (100%)
Intact 0/7 (0%) 1/24 (4%) 0/15 (0%)
Cranial nerve paresis
Facial 5/7 (71%) 13/24 (54%) 7/15 (47%)
Bulbar 6/7 (86%) 4/24 (17%) 2/15 (13%)
Extra-ocular 1/7 (14%) 0/24 (0%) 2/15 (13%)
Mechanical ventilation 3/7 (43%) 4/24 (17%) 2/15 (13%)
Autonomic dysfunction 2/7 (29%) 3/24 (13%) 2/15 (13%)
CSF protein, mg/dL (median, IQR) 360 (270–780) 114 (77–105) 100 (59–139)
CSF cells, n/mL (median, IQR) 0 (0–0) 1 (0–12) 3 (2–6)
CSF, ACD 7/7 (100%) 19/22 (86%) 11/14 (79%)
NCS type
AIDP 7/7 (100%) 21/24 (88%) 15/15 (100%)
Axonal 0/7 (0%) 3/24 (13%) 0/15 (0%)
Antecedent infection, positive/tested (%)
VZV 7/7 (100%) 6/6(100%) 6/6 (100%)
C. jejuni 1/7 (14%) 0/0 0/0
Other infections 0/7 (0%) 0/0 0/1 (0%)
Autoantibodies, positive/tested (%)
Anti-GM1 antibodies 0/7 (0%) 1/2 (50%) 1/2
Specific autoantibodies 0/0 0/1 (0%) 1/4 (25%)
Treatment
IVIG/PE 0/7 (0%) 14/23 (61%) 6/15 (40%)
Steroids 0/7 (0%) 0/23 (0%) 3/15 (20%)
Supportive care 7/7 (100%) 9/23 (39%) 6/15 (40%)
GBS disability scorec at 1 year
0 or 1 4/7 (57%) 16/22 (73%) 9/14 (64%)
2 3/7 (43%) 6/22 (27%) 3/14 (21%)
6 0/7 (0%) 0/22 (0%) 2/14 (14%)
ACD albuminocytologic dissociation
a Patient information is available in Supplementary Table 2
b Reported patients with post-shingles GBS were significantly older than our cohort and the reported post-chicken
pox GBS cohort (P < 0.0001)
c GBS disability score: 2 = able to walk 10 m unassisted but unable to run; 3 = able to walk 10 m with help; 4 =
bedridden or chair bound; 5 = requiring assisted ventilation; 6 = died
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42. Sensory abnormalities were strictly restricted to the distal
extremities in a stock and gloving distribution. Sensation was
impaired in six patients (impaired position sense in five pa-
tients; both impaired touch and position sense in one patient).
Cranial nerve involvement was present in six patients (facial
and bulbar cranial nerve dysfunction in five patients; extra-
ocular cranial nerve dysfunction in one patient; bulbar cranial
nerve dysfunction only in one patient; cranial nerves not in-
volved in one patient). Two patients experienced autonomic
dysfunction (both had hypertension and tachycardia) during
the first 2 months after the onset of weakness. Three patients
required mechanical ventilation (for 4, 30, and 45 days, re-
spectively). CSF was examined in all seven patients; the time-
point of the CSF tap ranged from 8 to 25 days after the onset of
weakness. All patients exhibited albuminocytologic dissocia-
tion in CSF (Table 1). All patients received supportive care;
none were treated with intravenous immunoglobulin or plas-
ma exchange.
Nerve electrophysiology
All seven patients underwent NCS; the time-point of NCS
ranged from 13 to 25 days after the onset of weakness. All
cases were neurophysiologically classified as demyelinating
GBS based on slowing of the motor nerves. NCS values are
summarized in Table 2. Prolonged distal latency in at least two
motor nerves was detected in all patients. Decreased motor
conduction velocity in at least two nerves was detected in
two patients. In-excitable distal sensory nerve action potential
(SNAP) in at least two individual nerves was found in six
patients; SNAPs were low in the other patient. Sural SNAP
was preserved (sural sparing pattern) in five cases.
Serology
Anti-VZV IgM antibodies were detected in all seven patients
(results were equivocal in two patients), and all patients were
also anti-VZV IgG-positive. Antibodies againstC. jejuniwere
not present in six cases; one patient had IgM antibodies
against C. jejuni. Antibodies against the ganglioside GM1
and C. jejuni LOS were not detected in any cases.
Furthermore, anti-VZV IgM antibodies were not detected in
a random selection of 19 patients with GBS who did not de-
velop cutaneous lesions in the 4 weeks preceding the onset of
weakness.
Outcome
Three patients were able to walk independently at 1 month,
and all seven patients could walk independently at 3 months
after the onset of weakness. Sensory dysfunction subsided
within 3 months in five of the six affected patients. Cranial
nerve dysfunction recovered within 4 months in five patients.
At 1 year, four patients were completely cured and three pa-
tients were able to run but had minor residual disabilities (par-
esthesia over the distal feet in one patient, unilateral facial
weakness in one patient, residual fatigue in one patient).
Literature review
Combined searches using the Boolean logic operators BAND^
and BOR^ identified 102 citations in PubMed and 79 citations
in EBSCO. Of the 105 unique results, 60 did not explore the
association between VZV and GBS, 10 were not in English,
and 5 described patients with VZV-related GBS but did not
mention the neurophysiological subtype; 30 articles were in-
cluded in the literature review. The demographic and clinical
features, neurophysiological subtypes, and serology for the 39
patients who developed GBS after VZV (primary VZV/
chicken pox, 24 cases; herpes zoster, 15 cases) reported in these
30 articles are summarized in Table 1; the details of individual
patients are illustrated in Supplementary Tables 1 and 2.
GBS following chicken pox or varicella
Of the 24 reported patients [13–32] who developed GBS after
chicken pox (Table 1), 17 (71%) were male (age range, 2 to
53 years old). Duration between skin rash and developing
weakness ranged from 4 to 21 days. Most patients were quad-
riplegic (83%) and had sensory symptoms (57%) and cranial
nerve dysfunction (62%). CSF albuminocytologic dissocia-
tion was noted in 86% (19/22) patients. Twenty-one (88%)
patients had evidence of the demyelinating form of GBS. At
1 year, 22 patients could walk independently; outcome was
not reported for two patients. Evidence of recent VZV infec-
tion in serum was present in all eight patients who were
screened for VZV. PCR to detect VZV in CSF was performed
for five patients; one patient was positive. Screening of other
infectious agents related to GBS was not performed for any
patient. Two patients were screened for anti-ganglioside anti-
bodies; anti-GM1 and anti-GD1b IgM were detected in one
patient. One patient was screened and negative for specific
autoantibodies to self-antigens. Lymphocyte subsets were ex-
amined in one patient; a marked decrease in suppressor T cells
and slight decrease in helper T cells with an inverted helper/
suppressor T cell ratio was observed.
GBS following herpes zoster or shingles
Among the 15 reported patients [29, 30, 33–42] who devel-
oped GBS after herpes zoster (Table 1), 10 (67%) were male
(age range, 42 to 77 years old). Duration between skin rash
and developing weakness was 3 to 42 days. All 15 patients
were quadriplegic, had sensory symptoms, and most had cra-
nial nerve dysfunction (71%). CSF albuminocytologic disso-
ciation was noted in 77% (10/13) patients. All 15 cases were
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reported to have the demyelinating form of GBS. Nine pa-
tients were reported to have a good clinical recovery, one
patient had residual motor weakness at 6 months, one patient
was bed-bound at 1 month (last follow-up), one patient was
not followed up and two patients died. Anti-VZV antibodies
were investigated in seven patients: anti-VZV IgM was de-
tected in both serum and CSF in three patients, in serum in
three patients, and in CSF in one patient. PCR was performed
for VZV in CSF in three patients; all were negative. Screening
for infectious agents related to GBS other than VZV was
Table 2 Nerve conduction study
data for the seven patients with
GBS following chicken pox
Patient number
1 2 3 4 5 6 7
Days from onset of weakness to NCS 18 20 14 13 25 14 18
Motor NCS
Median
dCMAPa 7.2 4.4 3.7 3.7 5.9 1.2 2.4
DMLb 5.1 7.0 9.1 9.0 6.7 10 7.0
MCVc 37 33 50 38 50 50 62
Ulnar
dCMAP 7.6 3.6 3.8 4.0 6.8 2.7 2.8
DML 3.8 6.0 7.0 5.1 4.6 5.7 5.7
MCV 40 37 58 43 51 51 56
Peroneal
dCMAP 1.5 1.0 1.7 1.3 13 1.8 1.7
DML 7.6 8.4 9.1 6.5 70 8.9 7.5
MCV 35 30 36 43 43 43 46
Tibial
dCMAP 1.0 1.5 3.6 0.9 3.5 4.3 1.5
DML 8.3 8.4 5.8 10 6.4 7.7 4.8
MCV 37 39 31 NA 42 40 38
Sensory NCS
Median
dSNAPd 7 NR NR NR NR NR NR
DSLe 3.1 NR NR NR NR NR NR
SCVf 41 NR NR NR NR NR NR
Ulnar
dSNAP 7 NR NR NR NR 17 NR
DSL 2.7 NR NR NR NR 2.8 NR
SCV 45 NR NR NR NR 50 NR
Sural
dSNAP 10 NR 12 19.5 10 NR 11
DSL 2.4 NR 2.3 1.8 3.0 NR 3.4
SCV 42 NR 52 50 47 NR 35
dCMAP distal compound muscle action potential, DML distal motor latency, MCV motor conduction velocity,
dSNAP distal sensory nerve action potential, DSL distal sensory latency, SCV sensory conduction velocity, NR
non-recordable
a Lower limit of normal (LLN) for dCMAP amplitude: median nerve, 4.5 mV; ulnar nerve, 7.9 mV; peroneal
nerve, 2 mV; tibial nerve, 5 mV
bUpper limit of normal (ULN) for DML:median nerve, 4.5 ms; ulnar nerve, 3.7 ms; peroneal nerve; 6.5 ms; tibial
nerve, 6.0 ms
c LLN for motor CV: median nerve, 50 m/s; ulnar nerve, 50 m/s; peroneal nerve, 40 m/s; tibial nerve, 40 m/s
d LLN for dSNAP amplitude: median nerve, 10 μV; ulnar nerve, 6 μV; sural nerve, 4 μV
eULN for DSL: median nerve, 3.2 ms; ulnar nerve, 3.1 ms; sural nerve, 3.6 ms
f LLN for SCV: median nerve, 50 m/s; ulnar nerve, 50 m/s; sural nerve, 40 m/s
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performed for one patient and yielded negative results. Anti-
ganglioside antibodies were not assessed in any patients.
Specific autoantibodies to self-antigens were screened—and
were absent—in one patient. Lymphocyte subsets were exam-
ined in two patients; one had an abnormal helper/suppressor T
cell ratio and the other (known HIV-positive) had decreased
CD4 T cells with a decreased CD4/CD8 T cell ratio.
Discussion
In Bangladesh, GBS associated with chicken pox or prima-
ry VZV infection has characteristic sensory-motor neurolog-
ic involvement, a demyelinating pattern on nerve electro-
physiology, and favorable clinical outcome. This is remark-
able, considering that the majority of Bangladeshi patients
with GBS have the axonal form of GBS. Although muscle
weakness at nadir was severe, the outcome at 1 year was
favorable for all seven patients even in the absence of
specific treatment; in comparison, patients with C. jejuni-
associated GBS in this region have a poor outcome [3].
The presence of anti-VZV IgM antibodies and absence of
anti-GM1 and C. jejuni-related LOS antibodies in our sev-
en patients—and absence of anti-VZV IgM antibodies and
presence of anti-GM1 and C. jejuni-related LOS antibodies
in patients with non-VZV-associated GBS—provides strong
evidence of an etiological role for VZV in GBS. The sys-
tematic review revealed most other reported cases of GBS
after VZV infection also had the sensory-motor type at
clinical presentation (> 50%) and neurophysiological evi-
dence of demyelination [13–42] (see Supplementary
Tables 1 and 2). Bulbar cranial nerve involvement, mechan-
ical ventilation, and residual disabilities appear more fre-
quent among our Bangladeshi patients than the previously
reported cases, possibly as none of our patients received
specific immunotherapy, e.g., intravenous immunoglobulin
or plasma exchange.
Varicella and shingles are the two clinical presentations of
VZV infection. Primary VZV infection (varicella or chicken
pox) typically presents with characteristic successive crops of
widespread maculo-vesiculo-pustular skin eruptions associat-
ed with fever. Reactivation of dormant VZV infection, known
as herpes zoster or shingles, characteristically presents with a
similar skin rash confined unilaterally to a specified dermato-
mal area. Among patients with GBS, both presentations of
VZV were predominantly associated with AIDP, the demye-
linating form.
In contrast to AMAN, the pathogenesis of AIDP is
largely unknown. Most patients with AMAN have preced-
ing C. jejuni infections. Carbohydrate mimicry between
C. jejuni LOS and peripheral nerve gangliosides triggers
production of cross-reactive, neurotoxic, anti-ganglioside
antibodies (e.g., GM1, GD1a, and GQ1b) [47]. In contrast,
patients with AIDP rarely have a preceding C. jejuni infec-
tion or ganglioside antibodies. AIDP may be mediated by
cytotoxic T cells, since extensive lymphocyte infiltration
into the myelin sheath was observed during autopsies of
three patients with AIDP [48], compared to a paucity of
lymphocytic infiltration in the axonal subtype [49]. The
CD4+ T cell subpopulation also differs in patients with
AIDP compared to the axonal subtype [50]. The role of
T cells in the pathogenesis of both AIDP and VZV infec-
tion is especially intriguing given the association between
the demyelinating form of GBS and VZV. VZV is known
to preferentially infect CD4+ memory T cells (with specific
tissue-homing characteristics) in the lymphoid tissues of the
upper respiratory tract, then T cells transport the virus to
the tissues that are ultimately infected [51]. Current evi-
dence suggests VZV actively remodels T cells into activat-
ed specific tissue-homing infected T cells. During the re-
modeling process, VZV induces a spectrum of changes in
the surface and intracellular proteins within heterogeneous
CD4 and CD8 T cell populations [52]. However, whether
this leads to autoimmunity against nerves has yet to be
determined. In addition, VZV can directly infect the periph-
eral nerves, which may produce the neurophysiologic fea-
tures of peripheral nerve demyelination [53]. However,
polyradiculoneuritis due to infection of nerve roots and/or
nerves by VZV is unlikely, since weakness did not coincide
with the skin rash in any case and none of the patients had
an increased CSF cell count. Immune-mediated demyelin-
ation is also possible in other acute and mono or polypha-
sic neurological disorders preceded by VZV infection, in-
cluding acute disseminated encephalomyelitis [54], acute
transvers myelitis (ATM) [55], or the relapse phase of mul-
tiple sclerosis [56], suggesting VZV has immune-mediated
demyelinating potential. In addition to a propensity for neu-
ronal tissue, VZV may also potentially trigger giant cell
arteritis (GCA), a form of autoimmune vasculopathy [57],
with the pathophysiology further indicating VZV-mediated
macrophase and T cell-mediated inflammation.
In terms of exploring the pathogenic role of VZV in GBS,
our study has several limitations. First, we did not perform
PCR for VZV in CSF or serum and hence cannot completely
exclude direct infection of the nerves by VZV. Second, we did
not carry out complete screening of infectious etiologies that
may trigger GBS (apart from VZV and C. jejuni), and third,
we did not perform lymphocyte subset assays to further ex-
plore the role of cell-mediated immune mechanisms in the
pathogenesis of GBS.
In conclusion, this study demonstrates VZV is associated
with the demyelinating form of GBS, distinct to the C. jejuni-
related axonal variants that predominate in Bangladesh.
Further studies are required to explore the mechanisms by
which VZV infection leads to damage to peripheral nerve
myelin.
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